Abstract Body

Background

Co-administration of rifampicin with tenofovir alafenamide fumarate (TAF) significantly reduces plasma tenofovir and intracellular tenofovir diphosphate (TFV-DP) concentrations. Standard dose TAF with rifampicin (RIF) was associated with TFV-DP concentrations that were markedly higher than those observed with tenofovir disoproxil fumarate (TDF) without rifampicin in healthy volunteers, however, data from people with TB/HIV-1 are needed to inform guidelines.

Methods

An open-label, three-period sequential PK study was conducted in participants with HIV-1 that were on antiretroviral therapy (ART) and virally suppressed, and who were also in the maintenance phase of therapy for RIF-sensitive TB. Steady-state TFV‑DP and plasma tenofovir concentrations were measured during three treatment periods: 1) TDF+RIF during the maintenance phase of TB therapy; 2) TAF+RIF after one month of treatment during the maintenance phase of TB therapy, and 3) TDF one month after completion of TB therapy. TAF and TDF were dosed at the standard daily doses (25 mg and 300 mg respectively) and were combined with efavirenz (600 mg), and either emtricitabine (200 mg) or lamivudine (300 mg). Area under the concentration-time curve over 24 hours (AUC0-24h) were estimated, and AUC0‑24h geometric mean ratios (GMR) with 95% confidence intervals (95% CI) were calculated to compare concentrations across periods.

Results

Eighteen participants were enrolled: median age of 41 years; 56% male. TAF+RIF was associated with a TFV-DP AUC0-24h GMR of 5.58 (95% CI 4.34, 7.17) and 5.43 (3.90, 7.55) when compared with TDF+RIF and TDF-only, respectively (Figure). The plasma tenofovir AUC0-24h GMR was 0.07 (0.06, 0.09) when treatment with TAF+RIF was compared with both TDF+RIF and TDF-only periods.

Conclusions

TAF and RIF co-administration was associated with higher TFV-DP concentrations than TDF, both with and without RIF. This study confirms previous findings among healthy volunteers and supports the co-administration of standard-dose TAF with RIF in the management of people with TB/HIV-1 co-infection. 

Table or Figure